NEW YORK (GenomeWeb News) – Atossa Genetics today said that revenues for 2012 increased sharply following the launch of two tests.

Separately, the company also said that it has entered into a $30 million stock purchase agreement with Aspire Capital.

The Seattle-based company brought in revenues of $481,842 in 2012, compared to $1,500 in 2011. Of that total $475,402 resulted from its diagnostic testing service, while $6,440 derived from sales of Atossa's MASCT Systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.